Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ALG1 like 9, pseudogene (ALG1L9P) is a genomic DNA sequence classified as a pseudogene, meaning it shares high sequence similarity to the functional ALG1 gene but does not encode a functional protein or enzyme[3][5]. It is located on chromosome 11 (chr11:71673885-71813859)[4]. Pseudogenes often arise from gene duplication or retrotransposition and may accumulate mutations that prevent normal gene expression or function[5]. Currently, there is no evidence that ALG1L9P has any biological function, involvement in disease, or utility as a drug target or biomarker[3][4][5]. ALG1L9P is nonfunctional and unrelated to the therapeutic enzyme encoded by the true ALG1 gene (mutations in ALG1 cause congenital disorders of glycosylation)[1][2]. The "pseudogene" designation indicates ALG1L9P is not a protein-coding or disease-associated target and thus not used in drug discovery or therapy[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ALG1 like 9, pseudogene (ALG1L9P).